Given the rarity of nasal and paranasal sinus rhabdomyosarcoma (SNRMS), there is a lack of literature on systemic treatment models for adult SNRMS, let alone prospective clinical studies. After referring to the literature, combining clinical practice and summarizing the previous treatment data of our center, we plan to conduct a prospective clinical trial: a study on the treatment of adult SNRMS with induction chemotherapy combined with radical chemoradiotherapy followed by adjuvant chemotherapy and surgery. The cumulative chemotherapy course is 8 (4 courses before radiotherapy and 4 courses after radiotherapy), and the total radiotherapy dose is 62-66Gy.

Inclusion Criteria:

• Age: 18-70 years old, gender not limited.
• Pathologically confirmed as rhabdomyosarcoma of the nasal cavity and paranasal sinuses.
• First-time treatment patients.
• Distant metastasis was ruled out through a comprehensive physical examination.
• Cases that met the inclusion criteria after joint discussion with rhinologists.
• Expected survival period ≥6 months.
• ECOG score: 0-2.

Exclusion Criteria:

• Patients whose distant metastasis has been clearly identified.
• Previously, chemotherapy, immunotherapy or biological targeted therapy has been applied to the target lesion; Patients whose target lesions have received radiotherapy or surgery (excluding biopsy).
• Functional impairment of vital organs

This study was conducted in patients with primary pathologically confirmed as rhabdomyosarcoma of the nasal cavity and paranasal sinuses without distant metastasis(subjects must have a measurable tumor lesion at baseline).